Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
86.11
+1.45 (1.71%)
At close: Dec 5, 2025, 4:00 PM EST
87.73
+1.63 (1.89%)
After-hours: Dec 5, 2025, 7:59 PM EST
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 139, with a low estimate of 121 and a high estimate of 150. The average target predicts an increase of 61.43% from the current stock price of 86.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Nov 25, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Oct 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $140 | Strong Buy | Maintains | $140 | +62.59% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
835.64M
from 675.04M
Increased by 23.79%
Revenue Next Year
1.18B
from 835.64M
Increased by 40.97%
EPS This Year
1.02
from 1.23
Decreased by -16.91%
EPS Next Year
1.35
from 1.02
Increased by 32.34%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 873.3M | 1.5B | ||||
| Avg | 835.6M | 1.2B | ||||
| Low | 791.7M | 994.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 29.4% | 74.5% | ||||
| Avg | 23.8% | 41.0% | ||||
| Low | 17.3% | 19.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.24 | 2.98 | ||||
| Avg | 1.02 | 1.35 | ||||
| Low | 0.79 | -0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.7% | 191.8% | ||||
| Avg | -16.9% | 32.3% | ||||
| Low | -35.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.